[go: up one dir, main page]

DK2929891T3 - Fremgangsmåde til modulering af appetitten - Google Patents

Fremgangsmåde til modulering af appetitten Download PDF

Info

Publication number
DK2929891T3
DK2929891T3 DK15163748.5T DK15163748T DK2929891T3 DK 2929891 T3 DK2929891 T3 DK 2929891T3 DK 15163748 T DK15163748 T DK 15163748T DK 2929891 T3 DK2929891 T3 DK 2929891T3
Authority
DK
Denmark
Prior art keywords
modulating
appearance
procedure
Prior art date
Application number
DK15163748.5T
Other languages
English (en)
Inventor
Samuel Norbert Breit
Asne Rhoda Bauskin
Original Assignee
St Vincents Hospital Sydney Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35149777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2929891(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from AU2004901957A external-priority patent/AU2004901957A0/en
Application filed by St Vincents Hospital Sydney Ltd filed Critical St Vincents Hospital Sydney Ltd
Application granted granted Critical
Publication of DK2929891T3 publication Critical patent/DK2929891T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/02—Nutritional disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/30—Psychoses; Psychiatry
    • G01N2800/303—Eating disorders, e.g. anorexia, bulimia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
DK15163748.5T 2004-04-13 2005-04-13 Fremgangsmåde til modulering af appetitten DK2929891T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2004901957A AU2004901957A0 (en) 2004-04-13 Method for modulating appetite
EP05729508.1A EP1734986B1 (en) 2004-04-13 2005-04-13 Method for modulating appetite

Publications (1)

Publication Number Publication Date
DK2929891T3 true DK2929891T3 (da) 2020-05-11

Family

ID=35149777

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15163748.5T DK2929891T3 (da) 2004-04-13 2005-04-13 Fremgangsmåde til modulering af appetitten
DK11183884.3T DK2441466T3 (da) 2004-04-13 2005-04-13 MIC-1-inhiberende middel

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK11183884.3T DK2441466T3 (da) 2004-04-13 2005-04-13 MIC-1-inhiberende middel

Country Status (11)

Country Link
US (7) US8192735B2 (da)
EP (4) EP1734986B1 (da)
JP (4) JP5448338B2 (da)
CA (2) CA2561877C (da)
CY (1) CY1115731T1 (da)
DK (2) DK2929891T3 (da)
ES (3) ES2788868T3 (da)
PL (2) PL2929891T3 (da)
PT (2) PT2929891T (da)
SI (1) SI2441466T1 (da)
WO (1) WO2005099746A1 (da)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2929891T3 (da) 2004-04-13 2020-05-11 St Vincents Hospital Sydney Ltd Fremgangsmåde til modulering af appetitten
CN106018820B (zh) * 2006-08-04 2018-04-27 汉诺威医学院 根据gdf-15评价心脏介入风险的工具与方法
EP2783698A1 (en) 2007-08-16 2014-10-01 St Vincent's Hospital Sydney Limited Agents and methods for modulating macrophage inhibitory cytokine (MIC-1) activity
US20100266707A1 (en) * 2007-10-09 2010-10-21 Samuel Norbert Breit Method of treating cachexia with the removal or inactivation of macrophage inhibitory cytokine-1
WO2010048670A1 (en) * 2008-10-31 2010-05-06 St Vincent's Hospital Sydney Limited Method of prognosis in chronic kidney disease
EP2694092B1 (en) 2011-04-08 2017-01-04 Amgen Inc. Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (gdf-15)
EP2807266B1 (en) 2012-01-26 2020-01-15 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
WO2013148117A1 (en) * 2012-03-27 2013-10-03 Ngm Biopharmaceuticals, Inc. Compositions and methods of use for treating metabolic disorders
SG11201502279YA (en) 2012-09-26 2015-04-29 Julius Maximilians Universität Würzburg Monoclonal antibodies to growth and differentiation factor 15 (gdf-15)
CN105073133B (zh) * 2012-12-21 2021-04-20 Aveo制药公司 抗gdf15抗体
US9161966B2 (en) 2013-01-30 2015-10-20 Ngm Biopharmaceuticals, Inc. GDF15 mutein polypeptides
BR112015018104A2 (pt) 2013-01-30 2017-11-21 Ngm Biopharmaceuticals Inc polipeptídeos de gdf15 modificados, seu uso, composições compreendendo os mesmos e recipiente estéril compreendendo as referidas composições
MX387211B (es) 2013-07-31 2025-03-18 Amgen Inc Construcciones del factor de diferenciacion de crecimiento 15 (gdf-15)
GB2524553C (en) * 2014-03-26 2017-07-19 Julius-Maximilians-Universitãt Würzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and uses thereof for treating cancer cachexia
GB2524552B (en) * 2014-03-26 2017-07-12 Julius-Maximilians-Universitãt Wurzburg Monoclonal antibodies to growth and differentiation factor 15 (GDF-15), and use thereof for treating cancer
PL3122775T3 (pl) * 2014-03-26 2020-05-18 Julius-Maximilians-Universität Würzburg Przeciwciała monoklonalne przeciwko czynnikowi wzrostu i różnicowania 15 (gdf-15) oraz ich zastosowanie do leczenia kacheksji nowotworowej i nowotworu
WO2015196145A1 (en) * 2014-06-20 2015-12-23 Aveo Pharmaceuticals, Inc. Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator
US20170137505A1 (en) * 2014-06-20 2017-05-18 Aveo Pharmaceuticals, Inc. Treatment of congestive heart failure and other cardiac dysfunction using a gdf15 modulator
EP3157942B1 (en) * 2014-06-23 2020-06-17 Novartis AG Site specific protein modifications
US10588980B2 (en) 2014-06-23 2020-03-17 Novartis Ag Fatty acids and their use in conjugation to biomolecules
JP6696915B2 (ja) 2014-06-24 2020-05-20 ノヴォ ノルディスク アー／エス Ｍｉｃ−１融合タンパク質及びその使用
SG10201802098UA (en) 2014-07-30 2018-04-27 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
ES2872534T3 (es) 2014-09-25 2021-11-02 Aveo Pharmaceuticals Inc Métodos para revertir la caquexia y prolongar la supervivencia que comprenden administrar un modulador de GDF15 y un agente anticanceroso
MY186702A (en) 2014-10-31 2021-08-11 Ngm Biopharmaceuticals Inc Compositions and methods of use for treating metabolic disorders
CN107108754A (zh) * 2014-12-22 2017-08-29 诺和诺德股份有限公司 α‑1‑抗胰蛋白酶(A1AT)融合蛋白及其用途
SMT202300017T1 (it) * 2015-10-02 2023-03-17 Univ Wuerzburg J Maximilians Terapia in combinazione usando inibitori del fattore della crescita e della differenziazione 15 (gdf-15) umano e bloccanti del punto di controllo immunitario
GB201517528D0 (en) 2015-10-02 2015-11-18 Julius Maximillians Universitãt Würzburg GDF-15 as a diagnosis marker for melanoma
KR102621034B1 (ko) 2015-10-02 2024-01-03 율리우스-막시밀리안스 우니버지태트 뷔르츠부르크 면역 체크포인트 차단제를 이용한 치료의 임상적인 경과를 예측하기 위한 진단 마커로서의 gdf-15
US11105818B2 (en) 2016-01-15 2021-08-31 Novo Nordisk A/S MIC-1 receptor and uses thereof
JP6829444B2 (ja) * 2016-02-29 2021-02-10 公立大学法人横浜市立大学 去勢抵抗性前立腺癌を検出する方法及び検出試薬
AU2017241161B2 (en) 2016-03-31 2022-05-26 Ngm Biopharmaceuticals, Inc. Binding proteins and methods of use thereof
EP3448887A1 (en) 2016-04-27 2019-03-06 Novartis AG Antibodies against growth differentiation factor 15 and uses thereof
CA3025251A1 (en) 2016-05-24 2017-11-30 Novo Nordisk A/S Mic-1 compounds and uses thereof
KR20190059312A (ko) * 2016-10-12 2019-05-30 얀센 바이오테크 인코포레이티드 Gdf15-유사 생물학적 활성의 조절제에 대한 스크리닝 방법
CN110072541B (zh) * 2016-12-06 2023-05-02 圣文森特医院悉尼有限公司 肥胖和饮食失调的治疗
GB201700567D0 (en) 2017-01-12 2017-03-01 Genagon Therapeutics Ab Therapeutic agents
TWI710377B (zh) 2017-05-23 2020-11-21 丹麥商諾佛 儂迪克股份有限公司 Ｍｉｃ－１化合物及其用途
WO2019004550A1 (ko) * 2017-06-26 2019-01-03 강원대학교 산학협력단 Mic-1 단백질에 특이적으로 결합하는 항체 및 이의 용도
JP7127422B2 (ja) * 2017-08-30 2022-08-30 東ソー株式会社 癌を検出する方法及び検出試薬
JP2020533302A (ja) 2017-09-10 2020-11-19 ノヴォ ノルディスク アー／エス 肥満の治療において使用するためのｍｉｃ−１およびｇｌｐ−１
KR20200140878A (ko) 2018-04-09 2020-12-16 암젠 인크 성장 분화 인자 15 융합 단백질
JP7155403B2 (ja) 2018-08-20 2022-10-18 ファイザー・インク 抗ｇｄｆ１５抗体、組成物および使用の方法
US10977522B2 (en) 2018-11-13 2021-04-13 CurieAI, Inc. Stimuli for symptom detection
WO2021067655A1 (en) 2019-10-04 2021-04-08 Amgen Inc. Use of gdf15 for treating cardiometabolic syndrome and other conditions
KR20210065057A (ko) 2019-11-26 2021-06-03 주식회사유한양행 지속형 gdf15 융합 단백질 및 이를 포함하는 약학 조성물
KR20230107309A (ko) 2020-11-10 2023-07-14 카탈임 게엠베하 항-gdf15 항체 및 암 치료용 투여 용법
AU2022251923A1 (en) 2021-03-31 2023-11-16 Cambridge Enterprise Limited Therapeutic inhibitors of gdf15 signalling
EP4351627A4 (en) 2021-05-21 2025-06-04 Yuhan Corporation COMPOSITION FOR COMBINATION THERAPY COMPRISING A GROWTH DIFFERENTIATION FACTOR 15 VARIANT AND A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST
WO2022245183A1 (en) 2021-05-21 2022-11-24 Yuhan Corporation Composition for preventing or treating non-alcoholic fatty liver disease or non-alcoholic steatohepatitis comprising growth differentiation factor-15 variant
EP4384545A1 (en) 2021-08-10 2024-06-19 BYOMass Inc. Anti-gdf15 antibodies, compositions and uses thereof
EP4452316A1 (en) 2021-12-22 2024-10-30 BYOMass Inc. Targeting gdf15-gfral pathway
WO2023154953A1 (en) 2022-02-14 2023-08-17 Ngm Biopharmaceuticals, Inc. Gdf15 polypeptides for treating and preventing autoimmune diseases

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0833912B1 (en) 1995-06-22 2009-02-25 St Vincent's Hospital Sydney Limited Novel tgf-beta like cytokine
WO1999006445A1 (en) 1997-07-31 1999-02-11 The Johns Hopkins University School Of Medicine Growth differentiation factor-15
EP2128260A3 (en) 1998-10-07 2010-06-16 STRYKER CORPORATION (a Michigan corporation) Modified TGF-beta superfamily proteins
CA2405680C (en) * 2000-04-20 2018-02-13 St. Vincent's Hospital Sydney Limited Diagnostic assay and method of treatment involving macrophage inhibitory cytokine -1 (mic-1)
AU2001288770A1 (en) * 2000-09-08 2002-03-22 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services A non-steroidal anti-inflammatory drug activated gene with anti-tumorigenic properties
US7157235B2 (en) * 2002-06-17 2007-01-02 St. Vincent's Hospital Sydney Limited Methods of diagnosis, prognosis and treatment of cardiovascular disease
DK2929891T3 (da) 2004-04-13 2020-05-11 St Vincents Hospital Sydney Ltd Fremgangsmåde til modulering af appetitten
PT1844337E (pt) * 2005-01-24 2014-04-03 Pepscan Systems Bv Compostos ligantes, compostos imunogénicos e peptidomiméticos
CN102369016A (zh) 2009-02-12 2012-03-07 史赛克公司 用于治疗系统性病症和疾病的包含TGF-β超家族成员的蛋白质的外周施用

Also Published As

Publication number Publication date
DK2441466T3 (da) 2014-10-27
PT2441466E (pt) 2014-09-09
JP5767667B2 (ja) 2015-08-19
HK1168274A1 (en) 2012-12-28
EP1734986A4 (en) 2009-07-22
ES2518865T3 (es) 2014-11-05
EP1734986A1 (en) 2006-12-27
CA2561877A1 (en) 2005-10-27
CA2561877C (en) 2017-03-14
EP2441466A1 (en) 2012-04-18
EP2929891B1 (en) 2020-03-11
ES2555956T3 (es) 2016-01-11
PL2441466T3 (pl) 2015-01-30
EP2441466B1 (en) 2014-07-23
EP2929891A1 (en) 2015-10-14
WO2005099746A1 (en) 2005-10-27
US20210340243A1 (en) 2021-11-04
HK1215932A1 (en) 2016-09-30
PT2929891T (pt) 2020-04-08
JP2013209376A (ja) 2013-10-10
CA2905125C (en) 2017-02-07
JP5806275B2 (ja) 2015-11-10
PL2929891T3 (pl) 2020-08-24
EP2774620A1 (en) 2014-09-10
US20250109192A1 (en) 2025-04-03
US20180346560A1 (en) 2018-12-06
EP1734986B1 (en) 2015-11-11
US20160289320A1 (en) 2016-10-06
JP2007532586A (ja) 2007-11-15
JP2011190262A (ja) 2011-09-29
US8946146B2 (en) 2015-02-03
US8192735B2 (en) 2012-06-05
US20150183861A1 (en) 2015-07-02
CY1115731T1 (el) 2017-01-25
SI2441466T1 (sl) 2015-01-30
ES2788868T3 (es) 2020-10-23
US20090004181A1 (en) 2009-01-01
JP2014051511A (ja) 2014-03-20
JP5448338B2 (ja) 2014-03-19
US20110123454A1 (en) 2011-05-26
CA2905125A1 (en) 2005-10-27

Similar Documents

Publication Publication Date Title
DK2929891T3 (da) Fremgangsmåde til modulering af appetitten
EP1958024A4 (en) ADVANCED ZSCREEN MODULATOR PROCEDURES
DK1748077T3 (da) Fremgangsmåde til fremstilling af protein
DK1753936T3 (da) Tætningssystem
DK1809978T3 (da) Modul-skydebane
DK1852430T3 (da) Fremgangsmåde til fremstilling af proanthocyanidinoligomer
DE602005012636D1 (de) Erung
DE602005011236D1 (de) Modulationsbereichstrigger
DK1593898T3 (da) Tætningselement
ATE442044T1 (de) Herbizid-safener-kombination
NL1029457A1 (nl) Androgeenmodulatoren.
DE602005012462D1 (de) Luftdämpfer
DK2447252T3 (da) Theramuteinmodulatorer
EP1718391A4 (en) SPRAY DEVICE
DK1789529T3 (da) Fremgangsmåde til forbedring af konserveringen af lactococcus
DK1834528T3 (da) Fremgangsmåde til fremstilling af gelé-agtige drikke
SE0400476L (sv) Komponent
DE602005010220D1 (de) Dichtung
SE0400530L (sv) Förfarande
ATE521769T1 (de) Beschlag
AT500162B1 (de) Gleitringdichtung
DE602005000799D1 (de) Flanschstruktur
DE602005000841D1 (de) Dichtung
DE602005002416T8 (de) Zündanordnung
DE602005025612D1 (de) Flächemodulationselement